Abstract | BACKGROUND:
Familial Mediterranean fever (FMF) is a rare inherited autosomal recessive autoinflammatory disorder characterized by recurrent and self-limited episodes of fever and painful serositis, lasting 1-3 days. FMF occurs almost exclusively among ethnic groups of the Mediterranean basin, although cases have also been found in Japan and Korean populations. Diagnosis is based on clinical features, response to colchicine and genetic analysis. Novel drugs are emerging, allowing better management of colchicine-resistant/ colchicine-intolerant patients. This review aims to attract the attention of the readers on differential diagnosis and management of patients with FMF. METHODS: The current state-of-the-art on FMF is outlined, with respect to epidemiological, genetic, pathophysiological and therapeutic characteristics, based on critical analysis of solid scientific literature. RESULTS: FMF is more frequent than it was thought before. The phenotypic expression of M694V is more severe than that of V726A. Patients with M694V/M694V homozygosity are exposed to a higher risk of developing renal amyloidosis, arthritis, dermatologic and oral lesions, higher fever and more frequent painful attacks. Life-long therapy with colchicine (1·0-2·4 mg/day) is effective and safe to prevent recurrent attacks and renal amyloidosis and to reverse proteinuria. In nonresponder patients, alternative novel approaches include interleukin-1 receptor antagonist anakinra and the interleukin-1 decoy receptor rilonacept. CONCLUSIONS:
|
Authors | Piero Portincasa, Giuseppe Scaccianoce, Giuseppe Palasciano |
Journal | European journal of clinical investigation
(Eur J Clin Invest)
Vol. 43
Issue 12
Pg. 1314-27
(Dec 2013)
ISSN: 1365-2362 [Electronic] England |
PMID | 24117178
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | © 2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. |
Chemical References |
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Interleukin 1 Receptor Antagonist Protein
- Recombinant Fusion Proteins
- rilonacept
- Colchicine
|
Topics |
- Amyloidosis, Familial
(prevention & control)
- Anti-Inflammatory Agents
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Colchicine
(therapeutic use)
- Diagnosis, Differential
- Early Diagnosis
- Familial Mediterranean Fever
(diagnosis, drug therapy, genetics)
- Genetic Testing
(methods)
- Homozygote
- Humans
- Interleukin 1 Receptor Antagonist Protein
(therapeutic use)
- Kidney Diseases
(genetics, prevention & control)
- Mutation
(genetics)
- Prognosis
- Recombinant Fusion Proteins
(therapeutic use)
|